SCHEMBL5365593

SCHEMBL5365593

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(Cl)c(O)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 4/20 0.55
EGFR P00533 3/20 0.55
IGF1R P08069 1/20 0.55
RAF1 P04049 2/20 0.50
SRC P12931 2/20 0.48
PLK4 O00444 1/20 0.48
PLK1 P53350 1/20 0.48
LRRK2 Q5S007 3/20 0.47
CDK2 P24941 2/20 0.47
KDR P35968 1/20 0.46
PDGFRB P09619 1/20 0.45
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
CTRC Q99895 1/20 0.45
NTRK1 P04629 1/20 0.45
FCER2 P06734 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365058 0.93 ERBB2 (0.64) ERBB2EGFRIGF1RRAF1SRC
SCHEMBL5369480 0.89 ERBB2 (0.56) ERBB2EGFRIGF1RRAF1SRC
SCHEMBL5359293 0.89 RAF1 (0.55) ERBB2EGFRIGF1RRAF1SRC
SCHEMBL5373158 0.87 ERBB2 (0.59) ERBB2EGFRIGF1RSRCPLK4
SCHEMBL5365035 0.86 ERBB2 (0.53) ERBB2EGFRIGF1RRAF1SRC
SCHEMBL5363069 0.85 SRC (0.51) ERBB2EGFRIGF1RSRCPLK4
SCHEMBL5368923 0.83 ERBB2 (0.59) ERBB2EGFRIGF1RSRCPLK4
SCHEMBL7139565 0.82 SRC (0.56) RAF1SRCPLK4LRRK2CDK2
SCHEMBL5368044 0.82 SRC (0.50) ERBB2EGFRIGF1RSRCCDK2
SCHEMBL5367150 0.82 RAF1 (0.61) ERBB2EGFRIGF1RRAF1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885IGF1R 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.